#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2794	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2550	326.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1934	1934	T	428	T,G	392,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2794	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2550	326.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1668	1668	C	412	C	370	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4510	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3896	347.3	0	.	n	.	0	T695C	SNP	695	695	T	1185	1185	C	358	C,A	317,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4510	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3896	347.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2461	2461	C	433	C	380	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4510	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3896	347.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2535	2535	A	459	A,G	395,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4510	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3896	347.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3087	3087	C	430	C,T,G	376,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4510	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3896	347.3	0	HET	.	.	.	C265T	.	265	265	C	755	755	C	368	C,T	161,157	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	486	folP	852	852	100.0	folP.l15.c4.ctg.1	1850	78.9	1	SNP	p	R228S	0	.	.	682	684	CGC	1173	1175	CGC	113;113;113	C;G;C	96;98;95	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	972	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3771	77.4	1	SNP	p	S91F	0	.	.	271	273	TCC	797	799	TCC	94;93;93	T;C;C	79;79;78	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	972	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3771	77.4	1	SNP	p	D95G	0	.	.	283	285	GAC	809	811	GAC	92;91;91	G;A,C;C	79;78,1;79	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	972	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3771	77.4	1	SNP	p	D95N	0	.	.	283	285	GAC	809	811	GAC	92;91;91	G;A,C;C	79;78,1;79	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	378	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1673	67.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	651	653	ACC	118;118;118	A,C;C;C	97,1;95;97	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	378	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1673	67.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	849	851	CAC	105;104;104	C;A;C	94;93;95	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	378	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1673	67.8	1	SNP	p	G45D	0	.	.	133	135	GGC	669	671	GGC	120;120;119	G;G;C	99;99;102	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	270	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1381	58.7	0	.	n	.	0	G120A	SNP	120	120	G	735	735	A	102	A	88	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1779	1781	GCA	120;120;121	G;C;A	105;107;106	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2262	2264	ATT	84;84;85	A;T;T	76;78;77	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	1	SNP	p	D86N	0	.	.	256	258	GAC	732	734	GAC	109;110;111	G;A;C	92;94;95	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	1	SNP	p	S87W	0	.	.	259	261	AGT	735	737	AGT	111;111;111	A;G;T	92;95;93	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	1	SNP	p	S87R	0	.	.	259	261	AGT	735	737	AGT	111;111;111	A;G;T	92;95;93	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	1	SNP	p	S87I	0	.	.	259	261	AGT	735	737	AGT	111;111;111	A;G;T	92;95;93	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	900	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3310	81.5	1	SNP	p	S88P	0	.	.	262	264	TCC	738	740	TCC	112;112;112	T;C;C	95;94;97	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	752	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3024	74.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1763	1765	GGC	102;102;102	G;G;C	86;85;85	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1337	1339	GCA	87;87;87	G;C;A	78;78;78	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1340	1342	ATC	88;88;90	A;T;C	77;76;78	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1352	1354	GTG	93;93;93	G;T;G	78;79;80	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1352	1354	GTG	93;93;93	G;T;G	78;79;80	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1856	1858	ACC	90;90;90	A;C;C	80;80;84	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1910	1912	GCG	95;95;95	G;C;G,T	80;76;76,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1910	1912	GCG	95;95;95	G;C;G,T	80;76;76,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2033	2035	GGT	85;86;86	G;G;T	73;72;73	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2042	2044	GGC	86;85;85	G;G;C	74;74;75	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	716	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2599	82.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2060	2062	CCG	81;81;81	C;C;G	73;73;74	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	976	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3411	85.9	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1682	1684	ACG	101;101;101	A;C;G	85;84;82	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	976	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3411	85.9	0	.	p	.	0	F666S	NONSYN	1996	1998	TTT	2555	2557	TCT	110;109;109	T;C,T;T	94;91,1;93	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	450	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2067	65.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	693	693	C	90	C	77	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	Y39H	NONSYN	115	117	TAC	612	614	CAC	101;102;102	C;A;C	84;85;85	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	T50A	NONSYN	148	150	ACT	645	647	GCT	106;105;106	G,T;C;T	88,1;89;89	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	K88N	NONSYN	262	264	AAA	759	761	AAC	94;94;94	A,G;A;C	80,1;80;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	E89T	NONSYN	265	267	GAA	762	764	ACA	94;94;90	A;C;A	80;81;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	S93N	NONSYN	277	279	AGC	774	776	AAC	88;89;90	A;A;C	76;76;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	H111R	NONSYN	331	333	CAT	828	830	CGT	91;91;91	C;G;T	84;85;85	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	N114S	NONSYN	340	342	AAC	837	839	AGC	91;90;90	A;G;C	84;85;83	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	I115V	NONSYN	343	345	ATC	840	842	GTC	90;90;91	G;T;C	84;83;85	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	R173H	NONSYN	517	519	CGC	1014	1016	CAC	78;79;79	C;A;C	71;72;71	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	S195F	NONSYN	583	585	TCC	1080	1082	TTC	93;92;92	T;T;C	80;77;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	N200S	NONSYN	598	600	AAT	1095	1097	AGT	87;88;88	A;G;T	76;80;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1203	1205	CGC	90;90;90	C;G;C	77;76;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	A249T	NONSYN	745	747	GCT	1242	1244	ACT	90;90;90	A;C;T	76;77;76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	454	porB1a	984	984	98.37	porB1a.l15.c4.ctg.1	1659	77.0	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1248	1250	GTG	90;90;90	G;T;G	77;77;74	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1756	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5079	103.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2114	2116	CAT	114;114;113	C;A;T	98;98;95	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	242	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1266	57.1	1	SNP	p	V57M	1	.	.	169	171	ATG	645	647	ATG	94;94;94	A;T;G	81;80;81	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
